PMID- 23069957
OWN - NLM
STAT- MEDLINE
DCOM- 20130104
LR  - 20161125
IS  - 1538-3652 (Electronic)
IS  - 0003-987X (Linking)
VI  - 148
IP  - 10
DP  - 2012 Oct
TI  - Golimumab-exacerbated subacute cutaneous lupus erythematosus.
PG  - 1186-90
LID - 10.1001/archdermatol.2012.1856 [doi]
AB  - BACKGROUND: Subacute cutaneous lupus erythematosus (SCLE) is characterized by 
      annular, nonscarring, photodistributed, or papulosquamous lesions. The disease 
      may be idiopathic, drug induced, or drug exacerbated. OBSERVATIONS: A 66-year-old 
      woman with a history of hypertension, parkinsonism, rheumatoid arthritis, anxiety 
      and depression, and symptoms of Sjogren syndrome was seen with a 1-month history 
      of an eruption on her upper extremities and upper trunk. The eruption had begun 2 
      to 3 weeks after subcutaneous injection of golimumab for rheumatoid arthritis. 
      She had developed SCLE 2 years previously due to furosemide use and 10 years 
      previously due to hydrochlorothiazide use. Physical examination revealed scaly, 
      annular, erythematous plaques photodistributed on the arms, legs, and upper 
      trunk. A punch biopsy specimen demonstrated vacuolar interface dermatitis and 
      lymphohistiocytic perivascular inflammation. Serological abnormalities included a 
      positive antinuclear antibody, an elevated anti-La/SS-B antibody level, and an 
      elevated anti-Ro/SS-A antibody level. She was diagnosed as having SCLE and was 
      initially treated with desonide lotion, photoprotection, prednisone (40 mg/d) 
      tapered over 6 weeks, and hydroxychloroquine sulfate (200 mg twice daily). 
      Because of persistent disease, methotrexate sodium (12.5 mg/wk) was subsequently 
      added to the regimen, and her eruption cleared completely. CONCLUSIONS: Golimumab 
      should be added to the list of medications capable of inducing or exacerbating 
      SCLE. Our patient demonstrated variable times to the resolution of SCLE, possibly 
      attributable in part to the different half-lives of the agents administered.
FAU - Wilkerson, Eric
AU  - Wilkerson E
AD  - Division of Dermatology, University of Louisville, Louisville, KY 40202, USA.
FAU - Hazey, Matthew A
AU  - Hazey MA
FAU - Bahrami, Soon
AU  - Bahrami S
FAU - Callen, Jeffrey P
AU  - Callen JP
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Arch Dermatol
JT  - Archives of dermatology
JID - 0372433
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antirheumatic Agents)
RN  - 886U3H6UFF (Chloroquine)
RN  - 91X1KLU43E (golimumab)
RN  - J280872D1O (Desonide)
RN  - VB0R961HZT (Prednisone)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Antibodies, Monoclonal/*adverse effects
MH  - Antirheumatic Agents/*adverse effects
MH  - Chloroquine/therapeutic use
MH  - Desonide/therapeutic use
MH  - Drug Eruptions/drug therapy/*etiology/pathology
MH  - Female
MH  - Humans
MH  - Lupus Erythematosus, Cutaneous/*chemically induced/drug therapy/pathology
MH  - Methotrexate/therapeutic use
MH  - Prednisone/therapeutic use
EDAT- 2012/10/17 06:00
MHDA- 2013/01/05 06:00
CRDT- 2012/10/17 06:00
PHST- 2012/10/17 06:00 [entrez]
PHST- 2012/10/17 06:00 [pubmed]
PHST- 2013/01/05 06:00 [medline]
AID - 1379279 [pii]
AID - 10.1001/archdermatol.2012.1856 [doi]
PST - ppublish
SO  - Arch Dermatol. 2012 Oct;148(10):1186-90. doi: 10.1001/archdermatol.2012.1856.